Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RSV MEDI ΔM2-2
- Development stage
- Phase 2
- Lead developer
- MedImmune
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intranasal
01
Overview
RSV MEDI ΔM2-2 is a live-attenuated respiratory syncytial virus (RSV) vaccine candidate developed through collaboration between the Laboratory of Infectious Diseases at NIAID/NIH and MedImmune. The vaccine features a deletion of the RSV M2-2 open reading frame (ORF), which results in decreased viral RNA replication while increasing antigen expression compared to previous live-attenuated RSV vaccine candidates. This unique modification 'de-links' virus replication and antibody response, priming for a potent anamnestic response following natural RSV infection. The vaccine is designed to prevent RSV infections, particularly in infants and young children at high risk for severe disease.
- Other names
- RSV MEDI deltaM2-2 vaccineRSV MEDI ΔM2-2RSV MEDI ΔM2-2 Lot RSV#002A
Beyond the preview
Go deeper on RSV MEDI ΔM2-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RSV MEDI ΔM2-2.